Activating Mutation in the Receptor Tyrosine Kinase FLT3 with Clinicopathological Relevance in Canine Mast Cell Tumors

Table 2

Clinical information and FLT3 mutation status of 20 dogs with mast cell tumour.

Case no.	Age	Sex	Histopathological grading (kiupel system)	FLT3 Exon 14/15 mutation	FLT3 Exon 20 mutation	WBC count (×10^3/µl)
1	12	M	Low	ITD	No	27.28
2	10	M	Low	ITD	No	29.80
3	10	F	Low	WT	No	11.25
4	8	M	High	WT	No	10..89
5	13	M	Low	ITD	No	12.76
6	8	M	High	WT	No	7.39
7	12	M	High	ITD	No	14.21
8	10	Fs	High	ITD	No	13.34
9	8	Fs	High	ITD	No	6.22
10	3	M	High	ITD	No	21.39
11	7	Mc	High	ITD	No	16.48
12	10	F	High	ITD	No	19.95
13	17	M	High	ITD	No	14.76
14	12	M	Low	ITD	No	13.62
15	13	M	Low	ITD	No	10.25
16	11	F	Low	WT	No	4.04
17	13	M	High	WT	No	9.70
18	12	M	Low	ITD	No	34.54
19	11	F	Low	WT	M	10.72
20	4	Mc	High	ITD	No	22.82

M = male, Mc = castrated male, F = female, Fs = spayed female, ITD = internal tandem duplication mutation, WT = wild-type, No = No mutation, M = mutation.